GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Incannex Healthcare Ltd (STU:IQI) » Definitions » Buyback Yield %

Incannex Healthcare (STU:IQI) Buyback Yield % : 0.11 (As of May. 21, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Incannex Healthcare Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Incannex Healthcare's current buyback yield was 0.11%.


Incannex Healthcare Buyback Yield % Historical Data

The historical data trend for Incannex Healthcare's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incannex Healthcare Buyback Yield % Chart

Incannex Healthcare Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -56.07 -23.27 -38.04 -5.40 -14.30

Incannex Healthcare Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.15 - - -

Competitive Comparison of Incannex Healthcare's Buyback Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Incannex Healthcare's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incannex Healthcare's Buyback Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Incannex Healthcare's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Incannex Healthcare's Buyback Yield % falls into.



Incannex Healthcare Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Incannex Healthcare's Buyback Yield for the fiscal year that ended in Jun. 2022 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 26.801) / 187.38785
=-14.30%

Incannex Healthcare's annualized Buyback Yield for the quarter that ended in Mar. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (0 + 0) * 4 / 0
=N/A%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Mar. 2024) data.


Incannex Healthcare Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Incannex Healthcare's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Incannex Healthcare (STU:IQI) Business Description

Traded in Other Exchanges
Address
8 Century Circuit Norwest, Suite 105, Sydney, NSW, AUS, 3000
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products.